About this trial
The brain is a metabolic active organ with constant energy demands. Brain oxygen supply is secured via cerebral circulation. Brain tumor surgery is commonly associated with the tumor's underlying pathophysiology including brain swelling or edema. During craniotomy for brain tumor resection maintenance of cerebral hemodynamic stability is of paramount importance. Neuroinflammation is also a normal response to trauma, such as in the case of brain tumor surgery. The role of neuroinflammation in postoperative brain function is well documented and the aim is to limit it through an appropriate anesthetic approach.
Anesthetic agents used during surgery affect brain homeostasis. The anesthetic agent of choice for neurosurgery should deliver smooth and hemodynamically stable anesthesia, good operating conditions, and allow early neurological assessment. Also, the ideal anesthetic agent should preserve cerebral perfusion and neuroprotection.
The two most common categories of anesthetic agents used nowadays for elective craniotomy are intravenous and inhalational agents.
Propofol is the intravenous anesthetic agent of choice. The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gamma-aminobutyric acid (GABA). Propofol causes a decrease in cerebral metabolic rate (CMR), intracranial pressure (ICP), cerebral perfusion pressure (CPP), and cerebral blood flow (CBF). It also is known for its antiemetic properties.
Volatile agents commonly used in neuroanesthesia clinical practice are sevoflurane and desflurane. Both of these agents decrease CMR while maintaining stable CPP. CBF alteration is dose-dependent. Desflurane evokes a greater cerebral vasodilation effect than sevoflurane. Sevoflurane is a well-known neuroprotective anesthetic agent traditionally used in neurosurgery. Both desflurane and sevoflurane are associated with early emergence.
Thus, this study aimed to explore the effect of volatile-based versus total intravenous anesthesia on cerebral homeostasis and neurocognitive function in patients undergoing elective craniotomy for brain tumor excision aiming to provide a basis for clinical rational drug use in patients undergoing craniotomy resection of supratentorial lesions.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
ASA-PS 1-3 (American Society of Anesthesiologists Physical Status classification)
Elective or semi-elective craniotomy for brain tumor resection
Signed informed consent
Disqualifiers
History of craniotomy at the same site
Morbid obesity
Delirious person before surgery
Cognitive disturbances
Trial design
Parallel
Treatments tested in this trial
Sevoflurane
DrugSevoflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
Desflurane
DrugDesflurane will be administered at concentrations maintaining MAC= 0.8 for the first 60 minutes , MAC=1.2 for the next 60 minutes and MAC= 0.8 until surgery completion.
Treatment groups
Trial outcomes
Primary outcomes
Changes in jugular venous oxygen saturation
Alterations in jugular venous oxygen saturation (%), after administration of sevoflurane or desflurane or propofol as anesthetic agent
Secondary outcomes
Changes in brain relaxation score
Alterations in BRS after administration of sevoflurane or desflurane or propofol as anesthetic agent
Changes in Μontreal Cognitive Assessment (MoCA)
Alterations in Μontreal Cognitive Assessment (MoCA) after administration of sevoflurane or desflurane or propofol as anesthetic agent.
Changes in GFAP
Alterations in GFAP (ng/ml) levels after administration of sevoflurane or desflurane or propofol as anesthetic agent.
Changes in UCH-L1
Alterations in UCH-L1 (ng/ml) after administration of sevoflurane or desflurane or propofol as anesthetic agent
Other outcomes
Changes in arterio-jugular oxygen difference (AjvDO2)
Alterations in arterio-jugular oxygen difference (AjvDO2 \[ml/dl\]), after after administration of sevoflurane or desflurane or propofol as anesthetic agent
Changes in arterio-jugular carbon dioxide difference (AjvCO2)
Alterations in arterio-jugular carbon dioxide difference (AjvCO2 \[mmHg\]), after administration of sevoflurane or desflurane or propofol as anesthetic agent
Changes in brain oxygen extraction ratio (O2Erbr)
Alterations in brain oxygen extraction ratio (O2Erbr \[%\]), after administration of sevoflurane or desflurane or propofol as anesthetic agent
Changes in Q-40
Alterations in Q-40 after administration of sevoflurane or desflurane or propofol as anesthetic agent
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Georgia Tsaousi
Lead sponsor
Aristotle University Of Thessaloniki
Sponsor institution